Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.2% during the fourth quarter, HoldingsChannel reports. The firm owned 18,557 shares of the company’s stock after buying an additional 578 shares during the period. 180 Wealth Advisors LLC’s holdings in Moderna were worth $772,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Axiom Advisory LLC boosted its position in Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after purchasing an additional 198 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in Moderna in the second quarter valued at $26,000. Arkadios Wealth Advisors boosted its holdings in shares of Moderna by 2.2% during the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock valued at $764,000 after acquiring an additional 243 shares during the period. Knuff & Co LLC grew its position in shares of Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after acquiring an additional 244 shares during the last quarter. Finally, Stephens Inc. AR grew its position in shares of Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after acquiring an additional 245 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 2.0 %

Shares of MRNA opened at $34.46 on Wednesday. The business’s 50-day moving average price is $41.78 and its 200 day moving average price is $67.79. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $13.26 billion, a P/E ratio of -5.92 and a beta of 1.60. Moderna, Inc. has a 1-year low of $31.94 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm posted ($1.39) earnings per share. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -9.3 earnings per share for the current year.

Analysts Set New Price Targets

MRNA has been the topic of several recent research reports. Wolfe Research began coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Jefferies Financial Group reduced their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Argus lowered Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. UBS Group cut their target price on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $78.83.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.